Alar Pharmaceuticals (ROCO:6785) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6785 Alar Pharmaceuticals Inc ROCO:6785
52 GF Score
Price NT$99.10
GF Value NT$96.48
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Alar Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

ROCO:6785
52GF Score
Alar Pharmaceuticals Inc ROCO:6785
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?

Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued. The current stock price of NT$99.10 is trading 2.7% above its estimated GF Value™ of NT$96.48. GuruFocus considers Alar Pharmaceuticals to be Fairly Valued.

Key valuation signals for ROCO:6785:

  • FFO per Share:
  • GF Value™: NT$96.48 vs. price of NT$99.10 (2.7% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alar Pharmaceuticals Business Description

Address Jhongke Road, No. 32, No. 2, 5th Floor, Situn District, Taichung, TWN, 428015
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score

Get the complete analysis for ROCO:6785

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$99.10
Price
NT$96.48
GF Value